Havent seen this part before re the Artimist project.Also good...

Havent seen this part before re the Artimist project.

Also good to see some info on the board of directors.

http://www.londonpharma.com/products/malaria.html

Malaria kills a child every 27 seconds. It is the greatest threat to young lives in the modern world. More than 40 per cent of the planet's population is exposed and most of them are also the poorest. Children are the most vulnerable because they have not lived long enough to build up immunity to the parasite. The majority of deaths are caused by failure to treat in time. Though huge efforts are being made to eradicate the scourge and malaria awareness programmes are in place throughout Africa, deaths are on the increase. Preventative treatments include expensive tablets, nets and spraying. Treatment for the infection has typically been tablets, injections and pessaries, all of which involve hospitalisation. Because most hospitals are a considerable distance from villages throughout Africa, victims – primarily children – can be malnourished, dehydrated or comatose by the time they reach a hospital. This makes traditional treatments difficult, if not impossible. Hence the terrible death toll of malaria. Our solution is non invasive and does not require hospitalisation.

ArTiMist is an anti-malarial sublingual spray that was developed for ProtoPharma Ltd by LondonPharma. ProtoPharma was acquired by LondonPharma in 2011. ArTiMist uses a drug called artemether which has proven anti-malarial effects. It has been formulated by us to be delivered subingually by those with little or no medical training. The product is a pre-treatment which can be administered to comatose children and has a rapid onset of action with positive results seen within six to eight hours. Patients recover sufficiently to move on to oral treatment as necessary. Our product can be kept for up to 12 months in non refrigerated conditions and the only equipment is the spray itself. The use of our delivery system eradicates the parasite within one day as opposed to four days with quinine. We are currently in Phase Three trials in multiple sites around sub-Saharan Africa, with very promising results being obtained daily.



Board of directors info located here - http://www.londonpharma.com/aboutus/bod.html